

# Enhanced Drug List Updates

July 2020

TRADE NAME (generic name)	Brand/Generic	
	Product	Description of Change
ACTEMRA (tocilizumab subcutaneous soln prefilled syringe 162 mg/0.9ml)	Brand	Addition, Preferred Status
ACTEMRA ACTPEN (tocilizumab subcutaneous soln auto-injector 162 mg/0.9ml)	Brand	Addition, Preferred Status
AYVAKIT (avapritinib tab 100 mg)	Brand	Addition, Preferred Status
AYVAKIT (avapritinib tab 200 mg)	Brand	Addition, Preferred Status
AYVAKIT (avapritinib tab 300 mg)	Brand	Addition, Preferred Status
CABOMETYX (cabozantinib s-malate tab 20 mg (base equivalent))	Brand	Addition, Preferred Status
CABOMETYX (cabozantinib s-malate tab 40 mg (base equivalent))	Brand	Addition, Preferred Status
CABOMETYX (cabozantinib s-malate tab 60 mg (base equivalent))	Brand	Addition, Preferred Status
DUAVEE (conjugated estrogens-bazedoxifene tab 0.45-20 mg)	Brand	Addition, Preferred Status
ERIVEDGE (vismodegib cap 150 mg)	Brand	Addition, Preferred Status
GLUCAGON EMERGENCY KIT FOR LOW BLOOD SUGAR (glucagon hcl for inj 1 mg)	Brand	Addition, Preferred Status
IBRANCE (palbociclib tab 100 mg)	Brand	Addition, Preferred Status
IBRANCE (palbociclib tab 125 mg)	Brand	Addition, Preferred Status
IBRANCE (palbociclib tab 75 mg)	Brand	Addition, Preferred Status
LOKELMA (sodium zirconium cyclosilicate for susp packet 10 gm)	Brand	Addition, Preferred Status
LOKELMA (sodium zirconium cyclosilicate for susp packet 5 gm)	Brand	Addition, Preferred Status
PREDNISOLONE ACETATE (prednisolone acetate ophth susp 1%)	Brand	Addition, Preferred Status
SIMPONI (golimumab subcutaneous soln auto-injector 100 mg/ml)	Brand	Addition, Preferred Status
SIMPONI (golimumab subcutaneous soln prefilled syringe 100 mg/ml)	Brand	Addition, Preferred Status
VELTASSA (patiomer sorbitex calcium for susp packet 16.8 gm (base eq))	Brand	Addition, Preferred Status
VELTASSA (patiomer sorbitex calcium for susp packet 25.2 gm (base eq))	Brand	Addition, Preferred Status
VELTASSA (patiomer sorbitex calcium for susp packet 8.4 gm (base eq))	Brand	Addition, Preferred Status
VUMERITY (dirroxime fumarate capsule delayed release 231 mg)	Brand	Addition, Preferred Status
VUMERITY (dirroxime fumarate capsule dr starter bottle 231 mg)	Brand	Addition, Preferred Status
XELJANZ (tofacitinib citrate tab 10 mg (base equivalent))	Brand	Addition, Preferred Status
XELJANZ (tofacitinib citrate tab 5 mg (base equivalent))	Brand	Addition, Preferred Status
XELJANZ XR (tofacitinib citrate tab er 24hr 11 mg (base equivalent))	Brand	Addition, Preferred Status
XELJANZ XR (tofacitinib citrate tab er 24hr 22 mg (base equivalent))	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.